May 30, 2018 PR-M05-18-NI-114
UPPSALA, Sweden, May 27, 2018 /PRNewswire/ -- Beactica, the Swedish drug discovery company with world-leading expertise in molecular interactions, today announced that it has signed a three-year extension of its master services agreement with Sanofi. The agreement outlines the legal terms under which Beactica and Sanofi collaborate on the characterization of interactions between novel therapeutics and their target proteins.
"We are pleased to extend our agreement with Sanofi and look forward to continuing our fruitful collaboration." said Dr Per Källblad, CEO of Beactica. "It is very rewarding to see tangible evidence on how Beactica's expertise and capabilities contribute towards products that increase the quality of life for patients living with compromised health conditions."
Beactica has established relationships with several global top-20 pharmaceutical companies as well as a growing number of biotech companies. The collaboration with Sanofi is ongoing since 2015.
Beactica AB contact
Per Källblad M.Sc. Ph.D.
CEO
per.kallblad@beactica.com
Tel: +46 18 56 08 80
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.